|
|
Volumn 54, Issue 6, 2014, Pages 658-662
|
|
Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
NON PRESCRIPTION DRUG;
ANTIINFECTIVE AGENT;
ANTIINFLAMMATORY AGENT;
DALBAVANCIN;
GASTROINTESTINAL AGENT;
GLYCOPEPTIDE;
MONOCLONAL ANTIBODY;
ORGANOPHOSPHATE;
ORITAVANCIN;
OXAZOLE DERIVATIVE;
TEDIZOLID;
TEICOPLANIN;
VEDOLIZUMAB;
ARTICLE;
COMORBIDITY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
MEDICATION COMPLIANCE;
MEDICATION REGIMEN COMPLEXITY INDICES;
MEDICATION THERAPY MANAGEMENT;
NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES;
PHARMACIST;
PHARMACY;
PHYSICIAN;
PRESCRIPTION;
TOTAL QUALITY MANAGEMENT;
ANALOGS AND DERIVATIVES;
ANIMAL;
IMMUNOLOGY;
INFLAMMATORY BOWEL DISEASES;
TREATMENT OUTCOME;
ANIMALS;
ANTI-BACTERIAL AGENTS;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
GASTROINTESTINAL AGENTS;
GLYCOPEPTIDES;
HUMANS;
INFLAMMATORY BOWEL DISEASES;
ORGANOPHOSPHATES;
OXAZOLES;
TEICOPLANIN;
TREATMENT OUTCOME;
|
|
EID: 84908887117
PISSN: 15443191
EISSN: 15443450
Source Type: Journal
DOI: 10.1331/JAPhA.2014.14543 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
